Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Facet Biotech PDL BioPharma, Inc. |
---|---|
Information provided by: | Facet Biotech |
ClinicalTrials.gov Identifier: | NCT00279422 |
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
Condition | Intervention | Phase |
---|---|---|
Ulcerative Colitis |
Drug: Visilizumab (Nuvion®; HuM291) |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 291-415 |
Study First Received: | January 17, 2006 |
Last Updated: | June 26, 2009 |
ClinicalTrials.gov Identifier: | NCT00279422 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Intravenous, Steroid-Refractory, Ulcerative Colitis |
Digestive System Diseases Gastrointestinal Diseases Ulcer Colonic Diseases Inflammatory Bowel Diseases |
Colitis, Ulcerative Intestinal Diseases Gastroenteritis Colitis |
Pathologic Processes Digestive System Diseases Gastrointestinal Diseases Ulcer Colonic Diseases |
Inflammatory Bowel Diseases Colitis, Ulcerative Intestinal Diseases Gastroenteritis Colitis |